Patient data acquisition and analysis approaches maximizing search for biomarkers considering clinical diagnostic diversity and genetic and epigenetic influence (CTMS# 22-0069)
This is a translational clinical study aiming to develop approaches to process effectively human tissues and identify biomarkers for painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN). This study will involve obtaining two skin biopsies representing affected and non-affected parts of each patient’s limb. Painful and non-painful neuropathies will be determined by a variety of standard approaches implemented by a neurologist Dr. Bhavaraju-Sanka.
Shraddha Dalwadi, MD Radiation Oncology
Federico Tozzi, MD Surgical Oncology, Surgery
A Multicenter Phase 1 Study to Determine the Maximum Tolerated Dose/ Maximum Feasible Dose, Safety, and Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered via Intraventricular Catheter for Leptomeningeal Metastases (CTMS# 21-0138)
This is an open-label, multicenter, Phase 1 dose-escalation study to establish the safety and tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) and to identify a maximum tolerated dose (MTD) and/or maximum feasible dose (MFD).